Ro offers Eli Lilly's new GLP-1 innovation

Ro, a direct-to-patient healthcare provider, is now offering Foundayo™ (orforglipron), a new GLP-1 medication developed by Eli Lilly. This marks a significant step in making innovative treatments more accessible to patients. Foundayo™ represents a new option in the growing field of metabolic health therapies. Ro's platform aims to streamline the patient experience, from consultation to prescription fulfillment. The availability of this new drug through Ro highlights the increasing integration of digital health solutions with pharmaceutical advancements, improving patient access to cutting-edge medical treatments.